{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 39,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a two-column layout to contrast the drug's engineering/profile with its biomarker/IP strategy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/8",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.55,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Strong IP position on GAS6 inhibition (>2035)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b40b79a-86ec-4c43-a628-936352257b4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.55,
        "y": 0.35
      },
      "kind": "list",
      "text": "Serum GAS6 levels associated with efficacy in preclinical studies; sAXL/GAS6 ratio pretreatment associated with response in P1b PROC, P1b ccRCC and P1b PDAC trials",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "435407e9-6e2d-4bca-b4d4-01cac8b8da8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "list",
      "text": "~200 fold greater affinity for human GAS6 compared to native AXL receptor; Preclinical data demonstrated relationship between affinity and anti-tumor activity; Good safety and PK profile; Structure modeled after marketed drugs (Enbrel, Zaltrap, Orencia)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f88a36d3-4993-4a52-82fe-9e60e849a90f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Proprietary biomarker tests to monitor GAS6 levels",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98906708-7370-45a4-97fb-7eefdee1f330",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6dce964-9583-41e5-b4dd-dcf45aef409d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "310f1ff5-a26a-4bf0-b2de-2afa35003828",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 7,
      "beatId": "11724964-5613-4be9-bf42-0171a9076bf3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 7-8 emphasize the limitations of current treatments and the potential benefits of Batiraxcept",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}